See more : Lang & Schwarz Aktiengesellschaft (LUS1.DE) Income Statement Analysis – Financial Results
Complete financial analysis of Entrada Therapeutics, Inc. (TRDA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Entrada Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Itaconix plc (ITXXF) Income Statement Analysis – Financial Results
- China Huarong Energy Company Limited (1101.HK) Income Statement Analysis – Financial Results
- Japan Communications Inc. (9424.T) Income Statement Analysis – Financial Results
- Ashoka Buildcon Limited (ASHOKA.NS) Income Statement Analysis – Financial Results
- Medigus Ltd. (MDGS) Income Statement Analysis – Financial Results
Entrada Therapeutics, Inc. (TRDA)
About Entrada Therapeutics, Inc.
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 129.01M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 99.88M | 1.90M | 1.12M | 326.00K | 104.00K |
| Gross Profit | 29.13M | -1.90M | -1.12M | -326.00K | -104.00K |
| Gross Profit Ratio | 22.58% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 99.88M | 66.61M | 35.93M | 21.10M | 8.22M |
| General & Administrative | 32.29M | 30.64M | 15.20M | 5.57M | 3.61M |
| Selling & Marketing | -1.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 32.29M | 30.64M | 15.20M | 5.57M | 3.61M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 6.27M |
| Operating Expenses | 132.18M | 97.25M | 51.13M | 26.67M | 11.82M |
| Cost & Expenses | 132.18M | 97.25M | 51.13M | 26.67M | 11.82M |
| Interest Income | 15.22M | 2.63M | 0.00 | 144.00K | 451.00K |
| Interest Expense | 0.00 | 2.63M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.84M | 1.90M | 1.12M | 326.00K | 104.00K |
| EBITDA | -321.00K | -95.35M | -50.01M | -26.34M | -11.72M |
| EBITDA Ratio | -0.25% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -3.16M | -97.25M | -51.13M | -26.67M | -11.82M |
| Operating Income Ratio | -2.45% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 15.22M | 2.63M | -31.00K | 144.00K | 6.72M |
| Income Before Tax | 12.06M | -94.62M | -51.16M | -26.52M | -5.10M |
| Income Before Tax Ratio | 9.34% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 18.74M | -7.16M | -1.09M | -144.00K | -451.00K |
| Net Income | -6.69M | -87.46M | -50.07M | -26.38M | -4.65M |
| Net Income Ratio | -5.18% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.20 | -2.79 | -1.60 | -0.84 | -0.15 |
| EPS Diluted | -0.20 | -2.79 | -1.60 | -0.84 | -0.15 |
| Weighted Avg Shares Out | 33.05M | 31.29M | 31.22M | 31.25M | 31.25M |
| Weighted Avg Shares Out (Dil) | 33.05M | 31.29M | 31.22M | 31.25M | 31.25M |
Entrada Therapeutics (TRDA) Is a Great Choice for 'Trend' Investors, Here's Why
Entrada Therapeutics (TRDA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Entrada Therapeutics, Inc. (TRDA) Reports Q3 Loss, Tops Revenue Estimates
Entrada Therapeutics, Inc. (TRDA) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.67. This compares to earnings of $1.02 per share a year ago.
Here's Why Momentum in Entrada Therapeutics (TRDA) Should Keep going
Entrada Therapeutics (TRDA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength"...
Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society
– Additional positive data from the Company's completed Phase 1 clinical trial evaluating ENTR-601-44 reinforces its safety profile and supports the planned Q4 2024 global regulatory filings for a Phase 2 clinical trial – – Preclinical data presented for the...
Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development
BOSTON, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines. Today, the Company...
āshibio Announces Appointment of Dipal Doshi, CEO of Entrada Therapeutics, to its Board of Directors
BRISBANE, Calif.--(BUSINESS WIRE)--āshibio, a privately held, clinical-stage biotechnology company developing novel therapeutics for the treatment of bone and connective tissue disorders, today announced the appointment of Dipal Doshi to its Board of Directors. Mr. Doshi currently serves as Chief Executive...
Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program
- Second annual DREAMS Grant Program awards $25,000 each to three U.S.-based non-profit organizations working to achieve greater equality for those living with Duchenne - - Announced in celebration of World Duchenne Awareness Day, grants are designed to fund efforts...
Entrada Therapeutics, Inc. (TRDA) Tops Q2 Earnings and Revenue Estimates
Entrada Therapeutics, Inc. (TRDA) came out with quarterly earnings of $1.55 per share, beating the Zacks Consensus Estimate of $0.65 per share. This compares to loss of $0.78 per share a year ago.
Wall Street Analysts See a 25.73% Upside in Entrada Therapeutics (TRDA): Can the Stock Really Move This High?
The mean of analysts' price targets for Entrada Therapeutics (TRDA) points to a 25.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside...
Entrada Therapeutics (TRDA) Moves 10.4% Higher: Will This Strength Last?
Entrada Therapeutics (TRDA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Source: https://incomestatements.info
Category: Stock Reports